Home › Research › Drug development
[Therapy Developments in Alzheimer's Disease]
Grimmer T.. Fortschritte der Neurologie-Psychiatrie, 2022-05-19
Topic: Amyloid, tau and blood-test diagnosis
The development of new therapies to treat Alzheimer's disease is a focus of global drug discovery. Research is being conducted into more potent therapies for symptomatic treatment, particularly for behavioral disturbances, but also into drugs that intervene in the pathophysiology of the disease, with the aim of halting or at least slowing the progression of the disease. To this end, the focus of identifying people with Alzheimer's disease is shifting to stages of pre-dementia such as that of Mild Cognitive Impairment (MCI), almost synonymous with prodromal AD, or even to asymptomatic stages.
Key findings
- Research is being conducted into more potent therapies for symptomatic treatment, particularly for behavioral disturbances, but also into drugs that intervene in the pathophysiology of the disease, with the aim of halting or at least slowing the progression of the disease.
- To this end, the focus of identifying people with Alzheimer's disease is shifting to stages of pre-dementia such as that of Mild Cognitive Impairment (MCI), almost synonymous with prodromal AD, or even to asymptomatic stages.
- Currently, passive immunization using monoclonal antibodies against Aβ42 has shown the most encouraging results.
- However, it has not been possible to demonstrate statistically significant differences on the primary target parameters in multiple completed pivotal trials.
Why it matters
This paper describes research into more potent symptomatic treatments, particularly for behavioral disturbances, and into drugs that intervene in the disease's pathophysiology with the aim of halting or at least slowing progression. It notes that the focus of identifying people with Alzheimer's disease is shifting to pre-dementia stages such as Mild Cognitive Impairment or even asymptomatic stages.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 30/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Fortschritte der Neurologie-Psychiatrie) |
| Journal's citation record | 0 / 4 | Fortschritte der Neurologie · Psychiatrie: journal h-index 48 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 1 / 6 | Cited 0.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Timo Grimmer: h-index 61 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Technical University of Munich: institution h-index 1,092 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35588740) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 30 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Grimmer, T. (2022). [Therapy Developments in Alzheimer's Disease]. Fortschritte der Neurologie-Psychiatrie. https://doi.org/10.1055/a-1802-4837
Vancouver
Grimmer T. [Therapy Developments in Alzheimer's Disease]. Fortschritte der Neurologie-Psychiatrie. 2022. doi:10.1055/a-1802-4837. PMID: 35588740.
BibTeX
@article{grimmer2022-35588740,
author = {Grimmer, T.},
title = {{[Therapy Developments in Alzheimer's Disease]}},
journal = {Fortschritte der Neurologie-Psychiatrie},
year = {2022},
doi = {10.1055/a-1802-4837},
pmid = {35588740},
url = {https://doi.org/10.1055/a-1802-4837}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.